OncoMatch/Clinical Trials/NCT07823660
Cardio-Oncology Rehabilitation in Breast Cancer Patients Undergoing Chemotherapy
Official title: Effect of Chemotherapy Treatment on the Cardiovascular System: Clinical Profile of Patients Diagnosed With Breast Cancer and an Integrated Cardio-Oncology Rehabilitation Approach. A Randomized Clinical Trial
Is NCT07823660 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for breast cancer.
Breast cancer is the most prevalent malignancy among women in Brazil, and Porto Alegre (Rio Grande do Sul) has one of the highest incidence rates in women under 50, with 165.5 cases per 100,000 women aged 40-49. Advances in cancer biology, treatment, and supportive care have improved outcomes, leading to increased survivorship. Regular physical exercise has been shown to be an effective strategy in both the prevention and management of breast cancer, and during chemotherapy, physical activity may reduce fatigue, improve quality of life, and increase cardiorespiratory fitness. This randomized clinical trial will enroll women diagnosed with breast cancer indicated for neoadjuvant or adjuvant chemotherapy. The study aims to characterize the clinical profile of these patients with respect to cardiovascular and functional effects of chemotherapy, and to evaluate an integrated cardio-oncology rehabilitation approach. The investigators expect to identify the clinical profile of breast cancer patients undergoing chemotherapy and establish associations with the study variables, as well as to assess the effect of a standardized exercise program on the cardiovascular and musculoskeletal systems and quality of life. Based on these results, the study aims to propose a complementary rehabilitation program, to be offered within the public health system, alongside pharmacological treatment during and after completion of the chemotherapy cycle.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Demographics
Lab requirements
Cardiac function
Cardiovascularly stable; LVEF <55% prior to initiation of chemotherapy [excluded]; prior diagnosis of ischemic heart disease, valvular heart disease, cardiac arrhythmias, myocarditis within 6 months, history of heart failure [excluded]
Cardiovascularly stable; LVEF <55% prior to initiation of chemotherapy [excluded]; prior diagnosis of ischemic heart disease, valvular heart disease, cardiac arrhythmias, myocarditis within 6 months, history of heart failure [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07823660 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages